AstraZeneca Plc’s COVID vaccine’s 90% efficacy came in younger group

The head of the U.S. Operation Warp Speed program said that the dose of AstraZeneca Plc’s COVID vaccine that showed the highest level of efficacy was tested among a younger population than a bigger dose that showed less efficacy.

Being developed with Oxford University, the vaccine was 90 per cent effective when a half-dose was given before a full-dose booster, said the partners. “The regime was administered to participants in a group whose age was capped at 55,” said Warp Speed’s Moncef Slaoui.

The researchers are still confused about the AstraZeneca report wondering why a smaller dose might have appeared to be more effective than a larger one.

Photo Credit :